ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

STELARA
Arthritis/rheumatic disorders
Colorectal disorders
Psoriasis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

STELARA Rx

Generic Name and Formulations:
Ustekinumab 45mg/0.5mL, 90mg/mL; soln for SC inj; or 130mg/26mL; soln for IV infusion; preservative-free.

Company:
Janssen Biotech, Inc.

Therapeutic Use:

Indications for STELARA:

Treatment of adults with active psoriatic arthritis; may be used alone or in combination with methotrexate.

Adult:

≥18yrs: initially 45mg SC once, then 4 weeks later, followed by 45mg every 12 weeks. Co-existent moderate-to-severe plaque psoriasis weighing >100kg: initially 90mg once, then 4 weeks later, followed by 90mg every 12 weeks. Rotate inj site.

Children:

<18yrs: not established.

Warnings/Precautions:

Active infections: do not initiate therapy. Chronic or history of recurrent infection. Conditions that predispose to infection. Increased risk of serious or fatal infections, esp. in IL-12/IL-23 genetically deficient patients (eg, mycobacteria, salmonella, BCG vaccines). Monitor for new infection; discontinue if serious infection develops. Test for and treat latent tuberculosis prior to initiating therapy. Avoid close contact with live vaccine recipients. History of malignancies. Monitor for appearance of non-melanoma skin cancer. Discontinue if reversible posterior leukoencephalopathy syndrome (RPLS) occurs or is suspected. Risk of noninfectious pneumonia; discontinue and treat if confirmed. Latex allergy (syringe). Elderly. Pregnancy. Nursing mothers.

Pharmacological Class:

Interleukin-12 and interleukin-23 antagonist.

Interactions:

Concomitant live vaccines, other immunosuppressants, phototherapy: not recommended. Do not give BCG vaccines during or within 1 year of starting or stopping ustekinumab. Non-live vaccines: may get suboptimal response. May affect CYP450 substrates. Caution with concomitant allergen immunotherapy (esp. for anaphylaxis).

Adverse Reactions:

Nasopharyngitis, upper respiratory tract infection, headache, fatigue; infections, malignancies, RPLS, hypersensitivity reactions (discontinue if occur).

Note:

Enroll pregnant women exposed to ustekinumab by calling (877) 311-8972.

Generic Availability:

NO

How Supplied:

Single-use vial (45mg/0.5mL, 130mg/26mL)—1; single-use prefilled syringe (45mg/0.5mL, 90mg/mL)—1


Data provided by MPR.

Indications for STELARA:

In moderately-to-severely active Crohn's disease: in adult patients who have failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed treatment with a tumor necrosis factor (TNF) blocker or, failed or were intolerant to treatment with ≥1 TNF blockers.

Adult:

Induction: give as a single IV infusion over 1hr. ≥18yrs (≤55kg): 260mg; (>55–85kg): 390mg; (>85kg): 520mg. Maintenance: 90mg by SC given 8 weeks after initial IV dose, then every 8 weeks thereafter. Rotate inj site.

Children:

<18yrs: not established.

Warnings/Precautions:

Active infections: do not initiate therapy. Chronic or history of recurrent infection. Conditions that predispose to infection. Increased risk of serious or fatal infections, esp. in IL-12/IL-23 genetically deficient patients (eg, mycobacteria, salmonella, BCG vaccines). Monitor for new infection; discontinue if serious infection develops. Test for and treat latent tuberculosis prior to initiating therapy. Avoid close contact with live vaccine recipients. History of malignancies. Monitor for appearance of non-melanoma skin cancer. Discontinue if reversible posterior leukoencephalopathy syndrome (RPLS) occurs or is suspected. Risk of noninfectious pneumonia; discontinue and treat if confirmed. Latex allergy (syringe). Elderly. Pregnancy. Nursing mothers.

Pharmacological Class:

Interleukin-12 and interleukin-23 antagonist.

Interactions:

Concomitant live vaccines, other immunosuppressants, phototherapy: not recommended. Do not give BCG vaccines during or within 1 year of starting or stopping ustekinumab. Non-live vaccines: may get suboptimal response. May affect CYP450 substrates. Caution with concomitant allergen immunotherapy (esp. for anaphylaxis).

Adverse Reactions:

Nasopharyngitis, upper respiratory tract infection, headache, fatigue; infections, malignancies, RPLS, hypersensitivity reactions (discontinue if occur).

Note:

Enroll pregnant women exposed to ustekinumab by calling (877) 311-8972.

Generic Availability:

NO

How Supplied:

Single-use vial (45mg/0.5mL, 130mg/26mL)—1; single-use prefilled syringe (45mg/0.5mL, 90mg/mL)—1


Data provided by MPR.

Indications for STELARA:

Moderate-to-severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy.

Adult:

12–17yrs: give SC at Weeks 0 and 4, then every 12 weeks thereafter. (<60kg): 0.75mg/kg; (60–100kg): 45mg; (>100kg): 90mg. ≥18yrs (≤100kg): initially 45mg SC once, then 4 weeks later, and then once every 12 weeks; (>100kg): initially 90mg once, then 4 weeks later, and then once every 12 weeks. Rotate inj site.

Children:

<12yrs: not established.

Warnings/Precautions:

Active infections: do not initiate therapy. Chronic or history of recurrent infection. Conditions that predispose to infection. Increased risk of serious or fatal infections, esp. in IL-12/IL-23 genetically deficient patients (eg, mycobacteria, salmonella, BCG vaccines). Monitor for new infection; discontinue if serious infection develops. Test for and treat latent tuberculosis prior to initiating therapy. Avoid close contact with live vaccine recipients. History of malignancies. Monitor for appearance of non-melanoma skin cancer. Discontinue if reversible posterior leukoencephalopathy syndrome (RPLS) occurs or is suspected. Risk of noninfectious pneumonia; discontinue and treat if confirmed. Latex allergy (syringe). Elderly. Pregnancy. Nursing mothers.

Pharmacological Class:

Interleukin-12 and interleukin-23 antagonist.

Interactions:

Concomitant live vaccines, other immunosuppressants, phototherapy: not recommended. Do not give BCG vaccines during or within 1 year of starting or stopping ustekinumab. Non-live vaccines: may get suboptimal response. May affect CYP450 substrates. Caution with concomitant allergen immunotherapy (esp. for anaphylaxis).

Adverse Reactions:

Nasopharyngitis, upper respiratory tract infection, headache, fatigue; infections, malignancies, RPLS, hypersensitivity reactions (discontinue if occur).

Note:

Enroll pregnant women exposed to ustekinumab by calling (877) 311-8972.

Generic Availability:

NO

How Supplied:

Single-use vial (45mg/0.5mL, 130mg/26mL)—1; single-use prefilled syringe (45mg/0.5mL, 90mg/mL)—1


Data provided by MPR.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs